Target Name: OIT3
NCBI ID: G170392
Review Report on OIT3 Target / Biomarker Content of Review Report on OIT3 Target / Biomarker
OIT3
Other Name(s): Liver-specific ZP domain-containing protein | liver-specific zona pellucida domain-containing protein | OIT3 variant 1 | Oncoprotein induced transcript 3, transcript variant 1 | oncoprotein induced transcript 3 | liver-specific ZP domain-containing protein | OIT3_HUMAN | Oncoprotein-induced transcript 3 protein | Liver-specific zona pellucida domain-containing protein | LZP

OIT3: A Drug Target / Disease Biomarker

OIT3, also known as interleukin-3, is a protein that is expressed in a variety of tissues throughout the body. It is a key regulator of immune responses and has been implicated in a number of diseases, including cancer, autoimmune disorders, and skin diseases.

One of the key functions of OIT3 is its role in the regulation of T cell development and function. T cells are a type of immune cell that play a critical role in protecting the body against infection and disease. OIT3 helps to ensure that T cells develop and differentiate into functional, responsive immune cells that are capable of recognizing and responding to foreign substances in the body.

In addition to its role in T cell development, OIT3 is also involved in the regulation of inflammation. When the body is exposed to an infection or other harmful substance, OIT3 helps to coordinate the immune response and ensure that appropriate amounts of inflammation are generated to eliminate the offending agent.

One of the things that makes OIT3 such a promising drug target is its ability to interact with a variety of different signaling pathways. This means that OIT3 can potentially be used to treat a wide range of diseases, depending on the specific signaling pathway that is being over-driven.

One potential mechanism by which OIT3 may be used to treat diseases is its ability to inhibit the production of pro-inflammatory cytokines. Pro-inflammatory cytokines, such as TNF-alpha and IL-1, are important molecules that are produced by the immune system in response to the presence of foreign substances in the body. OIT3 has been shown to be able to inhibit the production of these cytokines, which can help to reduce inflammation and improve overall health.

Another potential mechanism by which OIT3 may be used to treat diseases is its ability to enhance the production of anti-inflammatory cytokines. Anti-inflammatory cytokines, such as IL-10, are important molecules that help to counteract the pro-inflammatory effects of cytokines. OIT3 has been shown to be able to enhance the production of these cytokines, which can help to reduce inflammation and improve overall health.

In addition to its potential benefits for inflammation, OIT3 may also be used to treat other types of diseases. For example, OIT3 has been shown to be involved in the regulation of cell growth and has been implicated in the development of a variety of cancers. Additionally, OIT3 has been shown to be involved in the regulation of pain perception and may be used to treat chronic pain.

Overall, OIT3 is a protein that has the potential to be a drug target or biomarker for a wide range of diseases. Its ability to interact with a variety of different signaling pathways and its potential benefits for inflammation, T cell development, and cancer make it an attractive candidate for further research and potential clinical use.

Protein Name: Oncoprotein Induced Transcript 3

Functions: May be involved in hepatocellular function and development

The "OIT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OIT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P